



King's Research Portal

DOI:

[10.3389/fneur.2020.572850](https://doi.org/10.3389/fneur.2020.572850)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Reid, M., Beltran Lobo, P., Johnson, L., Gomez Perez-Nievas, B., & Noble, W. (2020). Astrocytes in Tauopathies. *Frontiers in Neurology*, 11, [572850]. <https://doi.org/10.3389/fneur.2020.572850>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Astrocytes in tauopathies

Matthew J. Reid¹, Paula Beltran-Lobo¹, Louisa Johnson¹, Beatriz Gomez Perez-Nievas¹,
Wendy Noble^{1*}

¹King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Basic and Clinical Neuroscience, 5 Cutcombe Road, London, SE5 9RX

*** Correspondence:**

Wendy Noble

wendy.noble@kcl.ac.uk

Keywords: tau, astrocyte, tauopathy, prion-like propagation, Alzheimer's disease, glia

Abstract

Tauopathies are a group of neurodegenerative diseases characterised by the progressive accumulation across the brain of hyperphosphorylated aggregates of the microtubule-associated protein tau that vary in isoform composition, structural conformation and localisation. Tau aggregates are most commonly deposited within neurons but can show differential association with astrocytes, depending on the disease. Astrocytes, the most abundant neural cells in the brain, play a major role in synapse and neuronal function, and are a key component of the glymphatic system and blood brain barrier. However, their contribution to tauopathy progression is not fully understood. Here we present a brief overview of the association of tau with astrocytes in tauopathies. We discuss findings that support a role for astrocytes in the uptake and spread of pathological tau, and we describe how alterations to astrocyte phenotype in tauopathies may cause functional alterations that impedes their ability to support neurons and/or cause neurotoxicity. The research reviewed here further highlights the importance of considering non-neuronal cells in neurodegeneration and suggests that astrocyte-directed targets that may have utility for therapeutic intervention in tauopathies.

Contribution to the field: Several neurodegenerative diseases, including Alzheimer's disease are characterised by the presence of abnormal tau deposits in affected brain regions, that is closely associated with synapse loss and neurodegeneration. Astrocytes, the most abundant neural cell type are an intrinsic component of synapses and regulate neuronal circuits. Recent evidence has highlighted an important contribution of astrocytes to the prion-like propagation of abnormal tau in Alzheimer's disease and related tauopathies. We discuss the evidence linking astrocytes with tauopathies, including their newly described roles in tau uptake/spread, highlighting the importance of continued work in this area.

1 Introduction

Tauopathies are a heterogeneous group of neurodegenerative diseases in which the deposition of hyperphosphorylated tau aggregates in affected brain regions accompanies synapse and neuron loss (Guo et al., 2016). Primary tauopathies exhibit tau aggregates as the predominant pathological hallmark and include a diverse family of frontal-temporal lobar dementia (FTLD) subtypes referred to as FTLD-tau, and includes progressive supranuclear palsy (PSP) and Pick's disease (PiD).

Alzheimer's disease (AD) is considered a secondary tauopathy owing to the presence of extracellular amyloid-beta (A β) plaques, and is the most common cause of dementia (Prince et al., 2014).

Tau proteins undergo several post-translational and other modifications in disease (Guo et al., 2016). Modified forms of tau spreads from the original site of deposition to anatomically connected regions by a "prion-like" mechanism, whereby tau proteopathic seeds passively recruit tau monomers (Jucker and Walker, 2018). The mechanisms underlying tau release, uptake and spread are not fully understood. It has long been acknowledged that in some tauopathies astrocytes accumulate tau leading to characteristic disease neuropathology. Accumulating evidence now suggests that astrocytes may actively participate in tau spread and/or clearance mechanisms by actively internalising tau. This review summarises the association of tau with astrocytes in tauopathies, and discusses the evidence implicating astrocytes in tau spread, as well as the impact of tauopathy brain environments on physiological astrocytic functions.

2 Tau protein

Human tau is encoded by the *MAPT* gene on chromosome 17 which comprises 16 exons. Exons 2, 3 and 10 undergo alternative splicing to produce the six main tau isoforms present in the adult human central nervous system (CNS) (Andreadis, 2005). Alternative splicing of exon 10 gives rise to tau isoforms containing either three or four microtubule binding repeats (referred to as 3R or 4R tau) in the C-terminal region, and alternative splicing of exons 2 and 3 produces tau proteins with zero, one or two inserts in the N-terminal tail (0N, 1N or 2N tau, respectively). A conserved proline-rich domain is found between these two spliced regions and is known to be important for tau interactions with other proteins, including actin (He et al., 2009). Tau isoforms are developmentally regulated; the shortest 0N3R isoform is expressed in the fetal brain whereas in the adult human brain 3R and 4R isoforms are equally represented (Goedert and Jakes, 1990). Tau has a number of key functions, the most recognised of which is stabilising microtubules in the axons of neurons, however tau roles in other important physiological functions such as axonal transport, DNA protection, cell signalling at the membrane, and synaptic vesicle release, have been described (Wang and Mandelkow, 2016; Guo et al., 2017). Tau is primarily expressed in neurons (Binder, 1985), but is known to be expressed to a lesser extent in glial cells (Zhang et al., 2014; Darmanis et al., 2015; Seiberlich et al., 2015; McKenzie et al., 2018).

Monomeric tau is water soluble and resists aggregation (Wang and Mandelkow, 2016). In tauopathies, tau undergoes extensive post-translational and other modifications including, but not limited to, phosphorylation, acetylation, nitration, SUMOylation, glycosylation, ubiquitination, cleavage and aggregation (Guo et al., 2017). The best studied of these is phosphorylation. There are 85 potential phosphorylation sites in 2N4R tau (Hanger et al., 2009) and increased phosphorylation of tau, alongside other tau modifications, can reduce tau affinity for microtubules, increase cytoplasmic tau concentrations and promote tau oligomerisation and aggregation (Guo et al., 2017). Differential extents of tau modifications lead to the accumulation of heterogeneous pools of modified tau between, and within, different tauopathies. Recently, Dujardin et al. (2020) found variations in relative abundance of soluble, oligomeric and seed-competent species of hyperphosphorylated tau in tauopathy brain. Specific post-translational modifications were found to influence tau seeding capacity, and tau seeding potential strongly correlated with the rate of clinical symptoms/disease progression.

The isoform composition of tau aggregates, as well as the structure of tau filaments, also differs between tauopathies. In AD, both paired helical and straight filaments contain identical protofilament

cores comprising residues 306-378 that define the aggregatory seed/core (Fitzpatrick et al., 2017). This structure differs from the folds of tau filaments observed in Pick's disease (Falcon et al., 2018) and tau filaments of chronic traumatic encephalopathy (CTE) have a unique hydrophobic core (Falcon et al., 2019). A novel fold in corticobasal degeneration (CBD) tau has now also been discovered (Zhang et al., 2020). These features may be important for the tau lesions that arise in different tauopathies (Table 1).

3 **Astrocytes in health and disease**

Astrocytes are organised into distinct domains, and each astrocyte can connect with thousands of neurons, allowing them to coordinate synaptic activity in the CNS (Parpura et al., 1994; Oberheim et al., 2006). Astrocytes were long considered as supporting cells in the brain, providing metabolic and nutritional support for neurons. However, astrocytes are critical for neuronal function due to their ability to sense changes in neuronal activity through their complement of cell surface receptors, and to modulate neuronal activity by releasing gliotransmitters and gliomodulators, as well as controlling the availability of glutamate, GABA and energy substrates (Parpura et al., 1994; Volterra and Meldolesi, 2005; Choi et al., 2014). Hence, astrocytes are now known to be actively involved in synaptic transmission (Santello et al., 2019), neural circuit maintenance (Mederos et al., 2018) and long-term potentiation (Lushnikova et al., 2009). In addition, astrocytic end-feet are a structural component of the blood-brain barrier (BBB), and together with endothelial cells and pericytes have a central role in the regulation of blood flow (Sofroniew and Vinters, 2010). Furthermore, astrocyte end-feet are crucial for the glymphatic system of the brain, a perivascular network that allows for exchange of interstitial and cerebrospinal fluid (CSF), providing a route for clearance of molecules and proteins including A β (Iliff et al., 2012; Simon et al., 2018).

In the neurodegenerative brain, astrocytes undergo pathological changes **in responses to changes in the local brain environment** that precede neuronal loss (Kersaitis et al., 2004). These morphologically and functionally modified astrocytes are often termed 'reactive'. Reactive astrocytes show considerable heterogeneity related to their localisation in the brain and the severity and length of injury/insult to their local environment (Zamanian et al., 2012). Reactive astrocytes are traditionally characterised by increased levels of glial fibrillary acidic protein (GFAP), which allows cytoskeletal and morphological arrangements as astrocytes alter their function (Kamphuis et al., 2015; Acosta et al., 2017). The accumulation of GFAP-immunopositive astrocytes is common in neurodegenerative diseases. For example, reactive astrocytes are often found surrounding plaques in AD (Bouvier et al., 2016; Osborn et al., 2016). Indeed, levels of GFAP-reactive astrocytes are closely associated with dementia in AD (Perez-Nievas et al., 2013). While increased GFAP is also found in aged brain (Wruck and Adjaye, 2020), new evidence suggests that there are subgroups of astrocytes, with varying levels of GFAP expression, that distinguish aging from AD, at least in mice (Habib et al., 2020). Alterations in GFAP expression have also been noted in primary tauopathies including PSP, PiD and corticobasal degeneration (CBD) (Ferrer et al., 2014).

Functional changes in reactive astrocytes are well-documented and include impaired gliotransmitter release (Piacentini et al., 2017), alterations in calcium signalling (Shigetomi et al., 2019), deficient ability to regulate glutamate levels at neuronal synapses and aberrant GABA release (Acosta et al., 2017). In addition, astrocytes are now recognised to contribute to neuroinflammatory responses that accelerate the progression of neurodegenerative diseases (Phillips et al., 2014; Bouvier et al., 2016; Bright et al., 2019). For example, reactive astrocytes increase their production and release of pro-inflammatory cytokines, complement components, and reactive oxygen species, alongside downregulating anti-inflammatory and repair proteins to induce neurotoxicity in diseased

environments (Lian et al., 2015; Bouvier et al., 2016; Leyns and Holtzman, 2017; Sadick and Liddel, 2019). Recent seminal findings proposed that astrocytes respond to their local environment by adopting “A1-neurotoxic” or “A2-neuroprotective” phenotypes (Liddel et al., 2017). Secretion of IL-1 α , TNF α , and C1q by microglia in response to damage, induces astrocytes to upregulate their expression of a specific cluster of “A1” genes, lose their trophic and synaptic support for neurons, and induce neuron death (Liddel et al., 2017). Markers of A1 astrocytes are upregulated in AD and other neurodegenerative diseases (Liddel et al., 2017), strongly implicating microglia-astrocyte communications in neurodegeneration. However, it is likely that there is a spectrum of reactive astrocyte states in different brain regions, throughout aging and disease progression (Boisvert et al., 2018; Habib et al., 2020), similar to dynamic microglial responses in disease (Vainchtein and Molofsky, 2020).

4 The association of astrocytes with tauopathy

Tau aggregates accumulate in both neurons and astrocytes in different tauopathies. In AD, tau aggregates containing both 3R and 4R tau deposit as intraneuronal neurofibrillary tangles and there is scant evidence of astrocytic tau inclusions (Garwood et al., 2017). In contrast, astrocytic tau pathology is the defining feature of several FTLT-tau subtypes (Table 1). In PSP, a neuropathological diagnosis criterion is ‘tufted’ astrocytes that show 4R tau aggregates in their proximal processes (Cairns et al., 2007; Kovacs and Budka, 2010). CBD has extensive clinical overlap with PSP. In CBD, astrocytic plaques containing 4R tau deposits that mark distal and end processes are an exclusive feature in most (Forrest et al., 2019), but not all (Ling et al., 2020) cases. Thread-like tau-positive astrocytic processes are also common in CBD (Dickson et al., 2011; Ling et al., 2016). Argrophilic grain disease (AGD) is a rare tauopathy that is characterised by 4R tau-immunopositive astrocytes, described as thorn-shaped and fuzzy/bush-like, in the medial temporal lobe (Botez et al., 1999; Saito et al., 2004; Forrest et al., 2019). In contrast, PiD is typically characterised by neuronal 3R tau inclusions, predominantly in granular neurons in the hippocampus, frontal and temporal cortices (Dickson, 2001; Josephs et al., 2011). ‘Ramified’ astrocytes immunopositive for tau have also been reported in PiD, but they are not considered a major pathological hallmark of the disease (Dickson et al., 2011; Ferrer et al., 2014). Several rarer tauopathy subtypes that show 4R tau-immunopositive globular inclusions, **predominantly in oligodendrocytes, and more rarely** in the cytoplasm and proximal processes of astrocytes, are collectively termed globular glial tauopathy (GGT) (Ahmed et al., 2013).

A spectrum of FTLT-tau subtypes that accumulate both 3R and 3R tau in neurofibrillary tangles (NFTs) typically occurring in cognitively normal aged individuals is referred as primary age-related tauopathy (PART) (Crary et al., 2014; Jellinger et al., 2015). Depending on the co-occurrence of A β pathology, PART can be histologically classified as “definite PART” in the absence of A β deposits, or “possible PART” when a limited number of A β deposits are present (Crary et al., 2014). Although the neuropathological characteristics of PART can overlap with other tauopathies, particularly AD, PART shows a lower threshold of amyloid load, and appears to have a more limited impact on cognition (Crary et al., 2014). Tau pathology in PART is predominantly neuronal and found in the CA2 hippocampal subfield, with little evidence of astrocytic tau deposits (Crary et al., 2014; Jellinger, 2018). In contrast, age-related tau astroglialopathy (ARTAG) describes a spectrum of abnormal tau pathology, predominantly in the aged brain, that is characterised by thorn-shaped and granular or fuzzy astrocytes containing phosphorylated tau (Kovacs et al., 2016; Kovacs, 2018). ARTAG can present alongside more typical tau pathology in tauopathies such as CBD (Kovacs et al., 2018, 2020), but is not always linked with dementia (Lace et al., 2012). In a recent detailed review, Kovacs et al. (2020) describe two distinct distribution patterns of ARTAG. They describe

ARTAG as a consequence of repeated mechanical damage (related to CTE), or chronic damage such as blood-brain barrier dysfunction. Furthermore, they propose that the location and type (white versus grey matter) of ARTAG pathology may result in decompensation of cognitive functions, the rate of which may be influenced by co-existing pathologies (Kovacs, 2020). It is important to note that the presence of astrocytic tau accumulations in the absence of dementia may suggest that tau-containing astrocytes are not damaging in tau-associated neurodegeneration, or at least in ARTAG, and may internalise tau aggregates as a means of clearing damaging protein species.

Finally, chronic traumatic encephalopathy (CTE) is caused by mild repetitive head injuries. 3R and 4R tau-positive aggregates are common in CTE, however the tau aggregates that accumulate in astrocytes are predominantly 4R and localize in astrocytes near small vessels in the cerebral sulci of the frontal and temporal cortices (McKee et al., 2013, 2015; Stein et al., 2014). Thorn-shaped astrocytes are also observed subpial and periventricular regions, **an interesting link to ARTAG** (McKee et al., 2016; Kovacs et al., 2020).

5 Do astrocytes contribute to tau pathology spread?

Neurofibrillary tangles have long been acknowledged to follow a stereotypical temporospatial pattern of spread from the entorhinal cortex as AD progresses (Braak et al., 2011). Recent evidence indicates that differences in the tau species that deposit in characteristic tau lesions may confer specific neuronal vulnerabilities and/or prion-like spread of tau (Clavaguera et al., 2013; Dujardin et al., 2020). Mouse models that express wild-type 3R and 4R human tau isoforms in appropriate ratios recapitulate the same cell type vulnerabilities that typify human tauopathies when injected with human tau extracts, including the development of tufted astrocytes in PSP tau-injected mice, and astroglial plaques in CBD tau-injected mice (He et al., 2020). These data raise the possibility that astrocytes actively contribute to the spread of pathological forms of tau, **particularly in PSP and CBD**. That tau spreads in a prion-like manner trans-synaptically along anatomical connections was elegantly shown in transgenic mice in which mutant human (P301L) FTLN-causing tau expression was restricted to layer II neurons in the entorhinal cortex. Following local tau aggregation, tau “seeds” were found to spread to the hippocampus and onwards as mice aged (De Calignon et al., 2012; Liu et al., 2012). Notably, PHF1-positive tau was detected in GFAP-positive astrocytes in the hippocampus of older mice, suggesting that astrocytes internalise and may contribute to tau spread (De Calignon et al., 2012) (Figure 1).

Heparan sulfate proteoglycans (HSPGs) are a well-conserved group of proteoglycans expressed on the cell surface of astrocytes and neurons (Turnbull et al., 2001; Sarrazin et al., 2011) that mediate targeted endocytosis (Turnbull et al., 2001), including that of purified prion proteins *in vitro* (Schonberger et al., 2003; Horonchik et al., 2005). HSPGs were recently shown to interact with protein aggregates including α -synuclein, A β and tau (Kanekiyo et al., 2011; Holmes et al., 2013; Ihse et al., 2017). HSPGs regulate the uptake of synthetic tau fibrils (Holmes et al., 2013) and human brain-derived tau (Puangmalai et al., 2020) in human immortalised cell lines and mouse primary neuronal cultures. HSPGs vary in the length of their glycosaminoglycan chains and sulfation patterns, properties that are important for tau uptake in human embryonic kidney cells (Stopschinski et al., 2018) and human iPSC derived neurons (Rauch et al., 2018). Interestingly, tau fibrils are efficiently internalised in a HSPG-dependent manner by primary astrocytes exogenously expressing transcription factor EB (TFEB), a master regulator of lysosomal biogenesis (Martini-Stoica et al., 2018). In contrast, monomeric tau appears to be taken up by astrocytes using an HSPG-independent mechanism (Perea et al., 2019). Together this suggests that multiple mechanisms are involved in tau

uptake by astrocytes, that may be specific to tau aggregation state or conformation, as well as the HSPG profile of the cell type (Tselnicker et al., 2014).

HSPGs can also partner with cell surface receptors to mediate the intake of protein aggregates. For example, HSPGs interact with members of the low-density lipoprotein receptor (LDLR) such as LRP1, to facilitate A β uptake and degradation by astrocytes (Kanekiyo and Bu, 2014; Liu et al., 2017). Knockdown of LRP1 was recently shown to block the uptake of monomeric and oligomeric tau in a human neuroglioma cell line, and partially inhibit uptake of sonicated tau fibrils (Rauch et al., 2020), warranting further investigation into how astrocytic LRP1 may mediate tau uptake and spread in tauopathies.

Astrocytes are an integral part of the glymphatic system of the brain, a clearance system of soluble proteins and solutes. The astrocytic water channel aquaporin-4 (AQP4), expressed at the astrocyte end feet, facilitates this process and is important for A β clearance (Benarroch, 2007; Iliff et al., 2012). Disruption to AQP4 may also contribute to tauopathy progression. In a mouse model of CTE, knockout of AQP4 exacerbated neurofibrillary tau pathology and neurodegeneration (Iliff et al., 2014). Distinct phosphorylation marks in AQP4 have been reported in human post-mortem ARTAG samples relative to controls (Ferrer et al., 2018) that are suggested to increase water permeability of AQP4. However, the functional implications of these modifications in ARTAG remain to be explored (Han et al., 1998; Kitchen et al., 2015). A recent transcriptional analysis of cognitively-impaired subjects and controls showed that components of the dystrophin-associated complex, which anchors AQP4 at the perivascular astrocytic end foot, are associated with phosphorylated tau levels in the temporal cortex (Simon et al., 2018). This analysis also revealed other astrocyte endfoot candidate genes that significantly correlate with temporal cortex tau pathology. The authors speculate that endfoot functions of astrocytes may play a role in the accumulation of tau aggregates throughout the brain. Although AQP4 might contribute to the clearance of aberrant proteins early in the disease process, this function could become impaired at later stages, hindering the clearance of pathogenic tau.

6 Tau effects on astrocyte function

In addition to potential roles in tau spread, internalisation of pathological forms of tau has been shown to disrupt a myriad of astrocytic functions, central for the maintenance and support of neurons. Oligomeric tau uptake alters calcium signalling and gliotransmitter release (e.g. ATP) via Ca²⁺-dependant mechanisms to disrupt post-synaptic currents and downregulate pre- and post-synaptic markers in neuronal-astrocyte co-cultures (Piacentini et al., 2017), together suggesting that tau-induced changes to astrocyte function are toxic to neighbouring neurons, at least *in vitro*. Astrocytes isolated from a transgenic tauopathy model (P301S) expressing a 4R mutant tau isoform also acquired early functional deficiencies that impaired their ability to support neurons in culture (Sidoryk-Wegrzynowicz et al., 2017). **Astrocytes from mouse models of tauopathies also show altered expression of neuronally regulated genes (Hasel et al., 2018), indicating that the accumulation of abnormal tau species is sufficient to drive transcriptional and likely functional changes in astrocytes, via altered neuron-astrocyte interactions.** In addition, human astrocytes differentiated from iPSCs harbouring FTD-causing *MAPT* mutations display an increased vulnerability to oxidative stress and elevated protein ubiquitination, alongside disease-associated transcriptomic alterations (Hallmann et al., 2017).

The immune-related functions of astrocytes are a major contributor to neuroinflammatory response that directly alter neuronal integrity in neurodegenerative diseases (Sofroniew and Vinters, 2010). In

particular, the complement cascade, which also involves microglia, has an important role in the accumulation of beta-amyloid pathology (Veerhuis et al., 2011; Lian et al., 2016). C3 is a major component of the complement cascade and is highly expressed in reactive astrocytes (Liddelow et al., 2017). C3, as well as its downstream receptor C3aR1, that is mainly expressed by microglia, (Zhang et al., 2014), is upregulated in postmortem tauopathy brain and correlates with cognitive decline during disease progression (Litvinchuk et al., 2018). Levels of C3 also correlate with tau amounts in AD CSF (Wu et al., 2019). Ablation of C3aR or C3 in mouse models of tauopathy reversed neuronal loss and neurodegeneration (Litvinchuk et al., 2018; Wu et al., 2019), alongside reduced numbers of GFAP-reactive hypertrophied astrocytes being apparent upon C3aR knockout (Litvinchuk et al., 2018). These data indicate that complement activation downstream of astrocyte reactivity may be an important driver of tauopathy.

Astrocytes, together with microglia, are also hypothesized to induce synaptic loss and neurotoxicity in tauopathies, as they do during development (Chung et al., 2013), through dysregulated synaptic pruning (Henstridge et al., 2019). Sleep deprivation is common in AD (Noble and Spires-Jones, 2019), where it is believed to be both a cause and consequence of neurodegenerative changes (Noble and Spires-Jones, 2019). Sleep deprivation leads to enhanced tau release and spread (Holth et al., 2019), alongside astrocyte-mediated synapse elimination (Bellessi et al., 2017). It is therefore possible that astrocyte engulfment of tau-containing synapses may be one route by which astrocytes contribute to tau spread in AD.

Ultimately, cross-talk between astrocytes and microglia forms part of a complex innate immune response that may be exacerbated during tauopathies in response to protein aggregates. Deeper investigation of these pathways may reveal novel targets that can be exploited to slow or halt disease progression.

7 Discussion

Recent evidence has highlighted that altered astrocyte functions have detrimental consequences for neurons and may be a driver of neurodegenerative diseases. Astrocytes are closely associated with the accumulation of pathological forms of tau in tauopathies. There is some evidence that astrocytes internalise tau aggregates, via mechanisms that are not yet fully understood, and contribute to tau pathology spread across the brain and tau aggregate clearance via the glymphatic system. However, astrocytes show significant regional heterogeneity and more work is needed to better understand the contribution of different astrocyte subtypes in affected brain regions at different disease stages. Such understanding may aid in the development of astrocyte-targeted therapies for tauopathies. Astrocyte-targeted therapeutic approaches have been well described elsewhere including by Sadik and Liddelow (2019), and could include antagonists that prevent tau uptake by astrocytes to reduce tau spread, agents that prevent the release of neurotoxic astrocyte secretions or their uptake by neurons, or therapies that restore physiological astrocyte functions including their trophic support for neurons and synapses, maintenance of the blood brain barrier, and roles in the glymphatic clearance of protein aggregates.

7 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

8 Author Contributions

MJR, PBL, LJ, BGP-N and WN wrote and edited the manuscript.

9 Funding

Work in our laboratories is supported by funding from Alzheimer’s Research UK, Medical Research Council, British Biotechnology and Biological Sciences Research Council, and the van Geest Charitable Foundation.

10 References

- Acosta, C., Anderson, H. D., and Anderson, C. M. (2017). Astrocyte dysfunction in Alzheimer disease. *J. Neurosci. Res.* 95, 2430–2447. doi:10.1002/jnr.24075.
- Ahmed, Z., Bigio, E. H., Budka, H., Dickson, D. W., Ferrer, I., Ghetti, B., et al. (2013). Globular glial tauopathies (GGT): Consensus recommendations. *Acta Neuropathol.* 126, 537–544. doi:10.1007/s00401-013-1171-0.
- Andreadis, A. (2005). Tau gene alternative splicing: Expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. *Biochim. Biophys. Acta - Mol. Basis Dis.* 1739, 91–103. doi:10.1016/j.bbdis.2004.08.010.
- Benarroch, E. E. (2007). Aquaporin-4, homeostasis, and neurologic disease. *Neurology* 69, 2266 LP – 2268. doi:10.1212/01.wnl.0000286385.59836.e2.
- Bellesi, M., de Vivo, L., Chini, M., Gilli, F., Tononi, G., and Cirelli, C. (2017). Sleep loss promotes astrocytic phagocytosis and microglial activation in mouse cerebral cortex. *J. Neurosci.* 37, 5263–5273. doi: 10.1523/jneurosci.3981-16.2017
- Besser, L. M., Crary, J. F., Mock, C., and Kukull, W. A. (2017). Comparison of symptomatic and asymptomatic persons with primary age-related tauopathy. *Neurology* 89, 1707–1715. doi:10.1212/WNL.0000000000004521.
- Binder, L. I. (1985). The distribution of tau in the mammalian central nervous system. *J. Cell Biol.* 101, 1371–1378. doi:10.1083/jcb.101.4.1371.
- Boisvert, M. M., Erikson, G. A., Shokhirev, M. N., and Allen, N. J. (2018). The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain. *Cell Rep.* 22, 269–285. doi:10.1016/j.celrep.2017.12.039.
- Botez, G., Probst, A., Ipsen, S., and Tolnay, M. (1999). Astrocytes expressing hyperphosphorylated tau protein without glial fibrillary tangles in argyrophilic grain disease. *Acta Neuropathol.* 98, 251–256. doi:10.1007/s004010051077.
- Bouvier, D. S., Jones, E. V., Quesseveur, G., Davoli, M. A., Ferreira, T. A., Quirion, R., et al. (2016). High Resolution Dissection of Reactive Glial Nets in Alzheimer’s Disease. *Sci. Rep.* 6, 1–15. doi:10.1038/srep24544.
- Braak, H., and Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–59. doi: 10.1111/j.1750-3639.1991.tb00661.x.
- Braak, H., Thal, D. R., Ghebremedhin, E., and Del Tredici, K. (2011). Stages of the Pathologic

- 339 Process in Alzheimer Disease: Age Categories From 1 to 100 Years. *J. Neuropathol. Exp.*
 340 *Neurol.* 70, 960–969. doi:10.1097/NEN.0b013e318232a379.
- 341 Bright, F., Ittner, L. M., and Halliday, G. M. (2019). Neuroinflammation in frontotemporal dementia.
 342 *Nat. Rev. Neurol.* 15. doi:10.1038/s41582-019-0231-z.
- 343 Cairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M. Y., Hatanpaa, K. J., et al.
 344 (2007). Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar
 345 degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta*
 346 *Neuropathol.* 114, 5–22. doi:10.1007/s00401-007-0237-2.
- 347 Choi, S. S., Lee, H. J., Lim, I., Satoh, J. I., and Kim, S. U. (2014). Human astrocytes: Secretome
 348 profiles of cytokines and chemokines. *PLoS One* 9. doi:10.1371/journal.pone.0092325.
- 349 Chung, W. S., Clarke, L. E., Wang, G. X., Stafford, B. K., Sher, A., Chakraborty, C., et al. (2013).
 350 Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. *Nature* 504,
 351 394–400. doi: 10.1038/nature12776
- 352 Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R. A., Frank, S., Hench, J., et al. (2013). Brain
 353 homogenates from human tauopathies induce tau inclusions in mouse brain. *Proc Natl Acad Sci*
 354 *U S A.* 110(23), 9535–40. doi: 10.1073/pnas.1301175110.
- 355 Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., et al.
 356 (2014). Primary age-related tauopathy (PART): a common pathology associated with human
 357 aging. *Acta Neuropathol.* 128, 755–766. doi:10.1007/s00401-014-1349-0.
- 358 Darmanis, S., Sloan, S. A., Zhang, Y., Enge, M., Caneda, C., Shuer, L. M., et al. (2015). A survey of
 359 human brain transcriptome diversity at the single cell level. *Proc. Natl. Acad. Sci. U. S. A.* 112,
 360 7285–7290. doi:10.1073/pnas.1507125112.
- 361 De Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J.,
 362 et al. (2012). Propagation of Tau Pathology in a Model of Early Alzheimer’s Disease. *Neuron*
 363 73, 685–697. doi:10.1016/j.neuron.2011.11.033.
- 364 Dickson, D. W. (2001). Neuropathology of Pick’s disease. *Neurology* 56, S16–S20.
 365 doi:10.1212/WNL.56.suppl_4.S16.
- 366 Dickson, D. W., Kouri, N., Murray, M. E., and Josephs, K. A. (2011). Neuropathology of
 367 frontotemporal lobar degeneration-Tau (FTLD-Tau). *J. Mol. Neurosci.* 45, 384–389.
 368 doi:10.1007/s12031-011-9589-0.
- 369 Dujardin, S., Commins, C., Lathuiliere, A., Beerepoot, P., Fernandes, A. R., Kamath, T. V., et al.
 370 (2020). Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease.
 371 *Nat. Med.* doi:10.1038/s41591-020-0938-9.
- 372 Falcon, B., Zhang, W., Murzin, A. G., Murshudov, G., Garringer, H. J., Vidal, R., et al. (2018).
 373 Structures of filaments from Pick’s disease reveal a novel tau protein fold. *Nature* 561, 137–
 374 140. doi:10.1038/s41586-018-0454-y.
- 375 Falcon, B., Zivanov, J., Zhang, W., Murzin, A. G., Garringer, H. J., Vidal, R., et al. (2019). Novel tau

- 376 filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. *Nature*.
377 doi:10.1038/s41586-019-1026-5.
- 378 Ferrer, I., García, M. A., González, I. L., Lucena, D. D., Villalonga, A. R., Tech, M. C., et al. (2018).
379 Aging-related tau astrogliopathy (ARTAG): Not only tau phosphorylation in astrocytes. *Brain*
380 *Pathol.* doi:10.1111/bpa.12593.
- 381 Ferrer, I., López-González, I., Carmona, M., Arregui, L., Dalfó, E., Torrejón-Escribano, B., et al.
382 (2014). Glial and neuronal tau pathology in tauopathies: Characterization of disease-specific
383 phenotypes and tau pathology progression. *J. Neuropathol. Exp. Neurol.* 73, 81–97.
384 doi:10.1097/NEN.0000000000000030.
- 385 Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., et al.
386 (2017). Cryo-EM structures of tau filaments from Alzheimer’s disease. *Nature* 547, 185–190.
387 doi:10.1038/nature23002.
- 388 Forrest, S. L., Kril, J. J., and Halliday, G. M. (2019). Cellular and regional vulnerability in
389 frontotemporal tauopathies. *Acta Neuropathol.* 138, 705–727. doi:10.1007/s00401-019-02035-7.
- 390 Forrest, S. L., Kril, J. J., Stevens, C. H., Kwok, J. B., Hallupp, M., Kim, W. S., et al. (2018). Retiring
391 the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal
392 tauopathies. *Brain* 141, 521–534. doi:10.1093/brain/awx328.
- 393 Garwood, C. J., Ratcliffe, L. E., Simpson, J. E., Heath, P. R., Ince, P. G., and Wharton, S. B. (2017).
394 Review: Astrocytes in Alzheimer’s disease and other age-associated dementias: a supporting
395 player with a central role. *Neuropathol. Appl. Neurobiol.* 43, 281–298. doi:10.1111/nan.12338.
- 396 Goedert, M., and Jakes, R. (1990). Expression of separate isoforms of human tau protein: correlation
397 with the tau pattern in brain and effects on tubulin polymerization. *EMBO J.* 9, 4225–4230.
398 doi:10.1002/j.1460-2075.1990.tb07870.x.
- 399 Guerreiro, R. J., Gustafson, D. R., and Hardy, J. (2012). The genetic architecture of Alzheimer’s
400 disease: Beyond APP, PSEN5 and APOE. *Neurobiol. Aging* 33, 437–456.
401 doi:10.1016/j.neurobiolaging.2010.03.025.
- 402 Guo, T., Noble, W., and Hanger, D. P. (2017). Roles of tau protein in health and disease. *Acta*
403 *Neuropathol.* 133, 665–704. doi:10.1007/s00401-017-1707-9.
- 404 Habib, N., McCabe, C., Medina, S., Varshavsky, M., Kitsberg, D., Dvir-Szternfeld, R., et al. (2020).
405 Disease-associated astrocytes in Alzheimer’s disease and aging. *Nat. Neurosci.*
406 doi:10.1038/s41593-020-0624-8.
- 407 Hallmann, A. L., Araúzo-Bravo, M. J., Mavrommatis, L., Ehrlich, M., Röpke, A., Brockhaus, J., et
408 al. (2017). Astrocyte pathology in a human neural stem cell model of frontotemporal dementia
409 caused by mutant TAU protein. *Sci. Rep.* 7, 1–10. doi:10.1038/srep42991.
- 410 Han, Z., Wax, M. B., and Patil, R. V (1998). Regulation of Aquaporin-4 Water Channels by Phorbol
411 Ester-dependent Protein Phosphorylation. *J. Biol. Chem.* 273, 6001–6004.
412 doi:10.1074/jbc.273.11.6001.

- 413 Hanger, D. P., Anderton, B. H., and Noble, W. (2009). Tau phosphorylation: the therapeutic
414 challenge for neurodegenerative disease. *Trends Mol. Med.* 15, 112–119.
415 doi:10.1016/j.molmed.2009.01.003.
- 416 Hasel, P., Dando, O., Jiwaji, Z., Baxter, P., Todd, A.C., Heron, S., Márkus, N.M., McQueen, J.,
417 Hampton, D.W., Torvell, M., Tiwari, S.S., McKay, S., Eraso-Pichot, A., Zorzano, A., Masgrau,
418 R., Galea, E., Chandran, S., Wyllie, D.J.A., Simpson, T.I., Hardingham, G.E. (2017). *Nat*
419 *Commun.* 8:15132.
- 420 He, H. J., Wang, X. S., Pan, R., Wang, D. L., Liu, M. N., and He, R. Q. (2009). The proline-rich
421 domain of tau plays a role in interactions with actin. *BMC Cell Biol.* 10. doi:10.1186/1471-
422 2121-10-81.
- 423 He, Z., McBride, J. D., Xu, H., Changolkar, L., Kim, S. jung, Zhang, B., et al. (2020). Transmission
424 of tauopathy strains is independent of their isoform composition. *Nat. Commun.* 11.
425 doi:10.1038/s41467-019-13787-x.
- 426 Henstridge, C.M., Tzioras, M., Paolicelli, R.C. (2019). Glial Contribution to Excitatory and
427 Inhibitory Synapse Loss in Neurodegeneration. *Front Cell Neurosci.* 13:63. doi:
428 10.3389/fncel.2019.00063.
- 429 Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., et al. (2013). Heparan
430 sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds.
431 *Proc. Natl. Acad. Sci.* 110, E3138–E3147. doi:10.1073/pnas.1301440110.
- 432 Holth, J.K., Fritsch, S.K., Wang, C., Pedersen, N.P., Cirrito, J.R., Mahan, T.E., Finn, M.B., Manis,
433 M., Geerling, J.C., Fuller, P.M., Lucey, B.P., Holtzman, D.M. (2019). The sleep-wake cycle
434 regulates brain interstitial fluid tau in mice and CSF tau in humans. *Science.* 363(6429):880-884.
435 doi: 10.1126/science.aav2546.
- 436 Horonchik, L., Tzaban, S., Ben-Zaken, O., Yedidia, Y., Rouvinski, A., Papy-Garcia, D., et al. (2005).
437 Heparan sulfate is a cellular receptor for purified infectious prions. *J. Biol. Chem.* 280, 17062–
438 17067. doi:10.1074/jbc.M500122200.
- 439 Ihse, E., Yamakado, H., Wijk, X. M. Van, Lawrence, R., and Esko, J. D. (2017). Cellular
440 internalization of alpha- synuclein aggregates by cell surface heparan sulfate depends on
441 aggregate conformation and cell type. *Sci. Rep.*, 1–10. doi:10.1038/s41598-017-08720-5.
- 442 Iliff, J. J., Chen, M. J., Plog, B. A., Zeppenfeld, D. M., Soltero, M., Yang, L., et al. (2014).
443 Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury.
444 *J. Neurosci.* 34, 16180–16193. doi:10.1523/JNEUROSCI.3020-14.2014.
- 445 Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., et al. (2012). A
446 paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of
447 interstitial solutes, including amyloid β . *Sci. Transl. Med.* 4. doi:10.1126/scitranslmed.3003748.
- 448 Jellinger, K. A., Alafuzoff, I., Attems, J., Beach, T. G., Cairns, N. J., Crary, J. F., et al. (2015).
449 PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. *Acta*
450 *Neuropathol.* 129, 757–762. doi:10.1007/s00401-015-1407-2.

- 451 Jellinger, K. A., and Attems, J. (2007). Neurofibrillary tangle-predominant dementia: Comparison
452 with classical Alzheimer disease. *Acta Neuropathol.* 113, 107–117. doi:10.1007/s00401-006-
453 0156-7.
- 454 Josephs, K. A., Hodges, J. R., Snowden, J. S., MacKenzie, I. R., Neumann, M., Mann, D. M., et al.
455 (2011). Neuropathological background of phenotypical variability in frontotemporal dementia.
456 *Acta Neuropathol.* 122, 137–153. doi:10.1007/s00401-011-0839-6.
- 457 Jucker, M., and Walker, L. C. (2018). Propagation and spread of pathogenic protein assemblies in
458 neurodegenerative diseases. *Nat. Neurosci.* 21, 1341–1349. doi:10.1038/s41593-018-0238-6.
- 459 Kamphuis, W., Kooijman, L., Orre, M., Stassen, O., Pekny, M., and Hol, E. M. (2015). GFAP and
460 vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and
461 changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease.
462 *Glia* 63, 1036–1056. doi:10.1002/glia.22800.
- 463 Kanekiyo, T., and Bu, G. (2014). The low-density lipoprotein receptor-related protein 1 and amyloid-
464 β clearance in Alzheimer's disease. *Front. Aging Neurosci.* 6, 1–12.
465 doi:10.3389/fnagi.2014.00093.
- 466 Kanekiyo, T., Zhang, J., Liu, Q., Liu, C. C., Zhang, L., and Bu, G. (2011). Heparan sulphate
467 proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major
468 pathways for neuronal amyloid- β uptake. *J. Neurosci.* 31, 1644–1651.
469 doi:10.1523/JNEUROSCI.5491-10.2011.
- 470 Kersaitis, C., Halliday, G. M., and Kril, J. J. (2004). Regional and cellular pathology in
471 frontotemporal dementia: Relationship to stage of disease in cases with and without Pick bodies.
472 *Acta Neuropathol.* 108, 515–523. doi:10.1007/s00401-004-0917-0.
- 473 Kitchen, P., Day, R. E., Taylor, L. H. J., Salman, M. M., Bill, R. M., Conner, M. T., et al. (2015).
474 Identification and Molecular Mechanisms of the Rapid Tonicity-induced Relocalization of the
475 Aquaporin 4 Channel. *J. Biol. Chem.* 290, 16873–16881. doi:10.1074/jbc.M115.646034.
- 476 Kovacs, G. G., and Budka, H. (2010). Current concepts of neuropathological diagnostics in practice:
477 Neurodegenerative diseases. *Clin. Neuropathol.* 29, 271–288. doi:10.5414/npp29271.
- 478 Kovacs, G. G., Ferrer, I., Grinberg, L. T., Alafuzoff, I., Attems, J., Budka, H., et al. (2016). Aging-
479 related tau astroglialopathy (ARTAG): harmonized evaluation strategy. *Acta Neuropathol.* 131,
480 87–102. doi:10.1007/s00401-015-1509-x.
- 481 Kovacs, G. G., Robinson, G. L., Xie, S.X., Lee, E.B., Grossman, M., Wolk, D.A., et al. (2017).
482 Evaluating the Patterns of Aging-Related Tau Astroglialopathy Unravels Novel Insights Into
483 Brain Aging and Neurodegenerative Diseases. *J Neuropathol Exp Neurol.* 76(4), 270–288. doi:
484 10.1093/jnen/nlx007
- 485 Kovacs, G. (2018). Understanding the Relevance of Aging-Related Tau Astroglialopathy (ARTAG).
486 *Neuroglia* 1, 339–350. doi:10.3390/neuroglia1020023.
- 487 Kovacs, G. G. (2020). Astroglia and Tau: New Perspectives. *Front. Aging Neurosci.* 12, 1–14.
488 doi:10.3389/fnagi.2020.00096.

- 489 Lace, G., Ince, P. G., Brayne, C., Savva, G. M., Matthews, F. E., de Silva, R., et al. (2012). Mesial
 490 Temporal Astrocyte Tau Pathology in the MRC-CFAS Ageing Brain Cohort. *Dement. Geriatr.*
 491 *Cogn. Disord.* 34, 15–24. doi:10.1159/000341581.
- 492 Lane, C. A., Hardy, J., and Schott, J. M. (2018). Alzheimer's disease. *Eur. J. Neurol.* 25, 59–70.
 493 doi:10.1111/ene.13439.
- 494 Leyns, C. E. G., and Holtzman, D. M. (2017). Glial contributions to neurodegeneration in
 495 tauopathies. *Mol. Neurodegener.* 12, 1–16. doi:10.1186/s13024-017-0192-x.
- 496 Lian, H., Litvinchuk, A., Chiang, A. C. A., Aithmitti, N., Jankowsky, J. L., and Zheng, H. (2016).
 497 Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in
 498 mouse models of alzheimer's disease. *J. Neurosci.* 36, 577–589.
 499 doi:10.1523/JNEUROSCI.2117-15.2016.
- 500 Lian, H., Yang, L., Cole, A., Sun, L., Chiang, A. C. A., Fowler, S. W., et al. (2015). NFκB-Activated
 501 Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function
 502 Associated with Alzheimer's Disease. *Neuron* 85, 101–115. doi:10.1016/j.neuron.2014.11.018.
- 503 Liddel, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., et al.
 504 (2017). Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* 541, 481–487.
 505 doi:10.1038/nature21029.
- 506 Sadick, J.S., Liddel, S.A. (2019). Don't forget astrocytes when targeting Alzheimer's disease. *Br J*
 507 *Pharmacol.* 176(18):3585-3598. doi: 10.1111/bph.14568.
- 508 Ling, H., Kovacs, G. G., Vonsattel, J. P. G., Davey, K., Mok, K. Y., Hardy, J., et al. (2016).
 509 Astroglial pathology predominates the earliest stage of corticobasal degeneration pathology. *Brain*
 510 139, 3237–3252. doi:10.1093/brain/aww256.
- 511 Litvinchuk, A., Wan, Y. W., Swartzlander, D. B., Chen, F., Cole, A., Propson, N. E., et al. (2018).
 512 Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network
 513 Deregulated in Tauopathy Models and Alzheimer's Disease. *Neuron* 100, 1337-1353.e5.
 514 doi:10.1016/j.neuron.2018.10.031.
- 515 Liu, C., Hu, J., Zhao, N., Wang, J., Wang, N., Cirrito, J. R., et al. (2017). Astrocytic LRP1 Mediates
 516 Brain Aβ Clearance and Impacts Amyloid Deposition. *J. Neurosci.* 37, 4023–4031.
 517 doi:10.1523/JNEUROSCI.3442-16.2017.
- 518 Liu, L., Drouet, V., Wu, J. W., Witter, M. P., Small, S. A., Clelland, C., et al. (2012). Trans-synaptic
 519 spread of tau pathology in vivo. *PLoS One* 7, 1–9. doi:10.1371/journal.pone.0031302.
- 520 Lushnikova, I., Skibo, G., Muller, D., and Nikonenko, I. (2009). Synaptic Potentiation Induces
 521 Increased Glial Coverage of Excitatory Synapses in CA1 Hippocampus. 762, 753–762.
 522 doi:10.1002/hipo.20551.
- 523 Martini-Stoica, H., Cole, A. L., Swartzlander, D. B., Chen, F., Wan, Y. W., Bajaj, L., et al. (2018).
 524 TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. *J. Exp.*
 525 *Med.* 215, 2355–2377. doi:10.1084/jem.20172158.

- 526 McKee, A. C., Cairns, N. J., Dickson, D. W., Folkerth, R. D., Dirk Keene, C., Litvan, I., et al. (2016).
527 The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the
528 diagnosis of chronic traumatic encephalopathy. *Acta Neuropathol.* 131, 75–86.
529 doi:10.1007/s00401-015-1515-z.
- 530 McKee, A. C., Stein, T. D., Kiernan, P. T., and Alvarez, V. E. (2015). The neuropathology of chronic
531 traumatic encephalopathy. *Brain Pathol.* 25, 350–364. doi:10.1111/bpa.12248.
- 532 McKee, A. C., Stein, T. D., Nowinski, C. J., Stern, R. A., Daneshvar, D. H., Alvarez, V. E., et al.
533 (2013). The spectrum of disease in chronic traumatic encephalopathy. *Brain* 136, 43–64.
534 doi:10.1093/brain/aws307.
- 535 McKenzie, A. T., Wang, M., Hauberg, M. E., Fullard, J. F., Kozlenkov, A., Keenan, A., et al. (2018).
536 Brain Cell Type Specific Gene Expression and Co-expression Network Architectures. *Sci. Rep.*
537 8, 1–19. doi:10.1038/s41598-018-27293-5.
- 538 Mederos, S., González-Arias, C., and Perea, G. (2018). Astrocyte–Neuron Networks: A Multilane
539 Highway of Signaling for Homeostatic Brain Function. *Front. Synaptic Neurosci.* 10, 1–12.
540 doi:10.3389/fnsyn.2018.00045.
- 541 Noble W, Spires-Jones TL. (2019). Sleep well to slow Alzheimer's progression? *Science*.
542 363(6429):813-814. doi: 10.1126/science.aaw5583.
- 543 Oberheim, N. A., Wang, X., Goldman, S., and Nedergaard, M. (2006). Astrocytic complexity
544 distinguishes the human brain. *Trends Neurosci.* 29, 547–553. doi:10.1016/j.tins.2006.08.004.
- 545 Osborn, L. M., Kamphuis, W., Wadman, W. J., and Hol, E. M. (2016). Astrogliosis: An integral
546 player in the pathogenesis of Alzheimer's disease. *Prog. Neurobiol.* 144, 121–141.
547 doi:10.1016/j.pneurobio.2016.01.001.
- 548 Parpura, V., Basarsky, T. A., Liu, F., and Jeftinijatt, K. (1994). Glutamate-mediated astrocyte-neuron
549 signalling. *Nature* 369, 744–747.
- 550 Perea, J. R., López, E., Díez-Ballesteros, J. C., Ávila, J., Hernández, F., and Bolós, M. (2019).
551 Extracellular Monomeric Tau Is Internalized by Astrocytes. *Front. Neurosci.* 13, 1–7.
552 doi:10.3389/fnins.2019.00442.
- 553 Perez-Nievas, B.G., Stein, T.D., Tai, H.C., Dols-Icardo, O., Scotton, T.C., Barroeta-Espar, I., et al.
554 (2013). Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. *Brain*.
555 136(Pt 8), 2510-26. doi: 10.1093/brain/awt171
- 556 Piacentini, R., Li Puma, D. D., Mainardi, M., Lazzarino, G., Tavazzi, B., Arancio, O., et al. (2017).
557 Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in
558 cultured hippocampal neurons. *Glia* 65, 1302–1316. doi:10.1002/glia.23163.
- 559 Prince, M., Albanese, E., Guerchert, M., Prina, M., Ferri, C., Mazzotti, D. R., et al. (2014). World
560 Alzheimer Report 2014: Dementia and Risk Reduction, an Analysis of Protective and
561 Modifiable Factors. *Alzheimer's Dis. Int.* Available at:
562 <https://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf>.

- 563 Puangmalai, N., Bhatt, N., Montalbano, M., Sengupta, U., Gaikwad, S., Mcallen, S., et al. (2020).
 564 Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer ' s
 565 disease , progressive supranuclear palsy and dementia with Lewy bodies. *Cell Death Dis.*
 566 doi:10.1038/s41419-020-2503-3.
- 567 Rauch, J. N., Chen, J. J., Sorum, A. W., Miller, G. M., Sharf, T., See, S. K., et al. (2018). Tau
 568 Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). *Sci.*
 569 *Rep.* 8, 1–10. doi:10.1038/s41598-018-24904-z.
- 570 Rauch, J. N., Luna, G., Guzman, E., Audouard, M., Challis, C., Sibih, Y. E., et al. (2020). LRP1 is a
 571 master regulator of tau uptake and spread. *Nature* 1, 1–5. doi:10.1038/s41586-020-2156-5.
- 572 **Rodriguez, R. D., and Grinberg, L. T. (2015). Argyrophilic grain disease: An underestimated**
 573 **tauopathy. *Dement. Neuropsychol.* 9, 2–8. doi:10.1590/S1980-57642015DN91000002.**
- 574 Sadick, J. S., and Liddelow, S. A. (2019). Don't forget astrocytes when targeting Alzheimer's
 575 disease. *Br. J. Pharmacol.* 176, 3585–3598. doi:10.1111/bph.14568.
- 576 Saito, Y., Ruberu, N. N., Sawabe, M., Arai, T., Tanaka, N., Kakuta, Y., et al. (2004). Staging of
 577 argyrophilic grains: An age-associated tauopathy. *J. Neuropathol. Exp. Neurol.* 63, 911–918.
 578 doi:10.1093/jnen/63.9.911.
- 579 Santello, M., Toni, N., and Volterra, A. (2019). Astrocyte function from information processing to
 580 cognition and cognitive impairment. *Nat. Neurosci.* 22, 154–166. doi:10.1038/s41593-018-
 581 0325-8.
- 582 Sarrazin, S., Lamanna, W. C., and Esko, J. D. (2011). Heparan Sulfate Proteoglycans. *Cold Spring*
 583 *Harb. Perspect. Biol.* 3, a004952–a004952. doi:10.1101/cshperspect.a004952.
- 584 Schonberger, O., Horonchik, L., Gabizon, R., Papy-Garcia, D., Barritault, D., and Taraboulos, A.
 585 (2003). Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis.
 586 *Biochem. Biophys. Res. Commun.* 312, 473–479. doi:10.1016/j.bbrc.2003.10.150.
- 587 Seiberlich, V., Bauer, N. G., Schwarz, L., Ffrench-Constant, C., Goldbaum, O., and Richter-
 588 Landsberg, C. (2015). Downregulation of the microtubule associated protein Tau impairs
 589 process outgrowth and myelin basic protein mRNA transport in oligodendrocytes. *Glia* 63,
 590 1621–1635. doi:10.1002/glia.22832.
- 591 Shigetomi, E., Saito, K., Sano, F., and Koizumi, S. C. (2019). Aberrant calcium signals in reactive
 592 astrocytes: A key process in neurological disorders. *Int. J. Mol. Sci.* 20.
 593 doi:10.3390/ijms20040996.
- 594 Sidoryk-Wegrzynowicz, M., Gerber, Y. N., Ries, M., Sastre, M., Tolkovsky, A. M., and Spillantini,
 595 M. G. (2017). Astrocytes in mouse models of tauopathies acquire early deficits and lose
 596 neurosupportive functions. *Acta Neuropathol. Commun.* 5, 89. doi:10.1186/s40478-017-0478-9.
- 597 Simon, M. J., Wang, M. X., Murchison, C. F., Roese, N. E., Boespflug, E. L., Woltjer, R. L., et al.
 598 (2018). Transcriptional network analysis of human astrocytic endfoot genes reveals region-
 599 specific associations with dementia status and tau pathology. *Sci. Rep.* 8, 1–16.
 600 doi:10.1038/s41598-018-30779-x.

- 601 Sofroniew, M. V., and Vinters, H. V. (2010). Astrocytes: biology and pathology. *Acta Neuropathol.*
602 119, 7–35. doi:10.1007/s00401-009-0619-8.
- 603 Stein, T. D., Alvarez, V. E., and McKee, A. C. (2014). Chronic traumatic encephalopathy: a
604 spectrum of neuropathological changes following repetitive brain trauma in athletes and military
605 personnel. *Alzheimers. Res. Ther.* 6, 4. doi:10.1186/alzrt234.
- 606 Stopschinski, B. E., Holmes, B. B., Miller, G. M., Manon, V. A., Vaquer-Alicea, J., Prueitt, W. L., et
607 al. (2018). Specific glycosaminoglycan chain length and sulfation patterns are required for cell
608 uptake of tau versus -synuclein and -amyloid aggregates. *J. Biol. Chem.* 293, 10826–10840.
609 doi:10.1074/jbc.RA117.000378.
- 610 Tselnicker, I. F., Boisvert, M. M., and Allen, N. J. (2014). The role of neuronal versus astrocyte-
611 derived heparan sulfate proteoglycans in brain development and injury. *Biochem. Soc. Trans.*
612 42, 1263–1269. doi:10.1042/BST20140166.
- 613 Turnbull, J., Powell, A., and Guimond, S. (2001). Heparan sulfate: Decoding a dynamic
614 multifunctional cell regulator. *Trends Cell Biol.* 11, 75–82. doi:10.1016/S0962-8924(00)01897-
615 3.
- 616 Vainchtein, I. D., and Molofsky, A. V. (2020). Astrocytes and Microglia: In Sickness and in Health.
617 *Trends Neurosci.* 43, 144–154. doi:10.1016/j.tins.2020.01.003.
- 618 Veerhuis, R., Nielsen, H. M., and Tenner, A. J. (2011). Complement in the brain. *Mol. Immunol.* 48,
619 1592–1603. doi:10.1016/j.molimm.2011.04.003.
- 620 Volterra, A., and Meldolesi, J. (2005). Astrocytes, from brain glue to communication elements: The
621 revolution continues. *Nat. Rev. Neurosci.* 6, 626–640. doi:10.1038/nrn1722.
- 622 Wang, Y., and Mandelkow, E. (2016). Tau in physiology and pathology. *Nat. Rev. Neurosci.* 17, 5–
623 21. doi:10.1038/nrn.2015.1.
- 624 Wruck, W., and Adjaye, J. (2020). Meta-analysis of human prefrontal cortex reveals activation of
625 GFAP and decline of synaptic transmission in the aging brain. *Acta Neuropathol. Commun.* 8,
626 1–18. doi:10.1186/s40478-020-00907-8.
- 627 Wu, T., Dejanovic, B., Gandham, V. D., Carano, R. A. D., Sheng, M., Hanson, J. E., et al. (2019).
628 Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in
629 Mouse Models of Amyloidosis and Tauopathy Article Complement C3 Is Activated in Human
630 AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and T.
631 *CellReports* 28, 2111–2123.e6. doi:10.1016/j.celrep.2019.07.060.
- 632 Zamanian, J. L., Xu, L., Foo, L. C., Nouri, N., Zhou, L., Giffard, R. G., et al. (2012). Genomic
633 analysis of reactive astrogliosis. *J. Neurosci.* 32, 6391–6410. doi:10.1523/JNEUROSCI.6221-
634 11.2012.
- 635 Zhang, W., Tarutani, A., Newell, K. L., Murzin, A. G., Matsubara, T., Falcon, B., et al. (2020).
636 Novel tau filament fold in corticobasal degeneration. *Nature* 580. doi:10.1038/s41586-020-
637 2043-0.

Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O’Keeffe, S., et al. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J. Neurosci.* 34, 11929–11947. doi:10.1523/JNEUROSCI.1860-14.2014.

11 Figure legends

Figure 1. Astrocytic mechanisms that may contribute to spread of tau pathology. 1) Tau monomers and aggregates are released from neurons via various mechanisms, including from the pre-synapse, 2) Astrocytes have specific HSPGs and receptors such as LDR1 that may mediate the uptake of tau aggregates, 3) These aggregates may be internalised and processed by various mechanisms, include lysosomal degradation, 4) Disruption of AQP4 in perivascular astrocytic end-feet may contribute to the disrupted tau clearance and the accumulation of tau aggregates in the CNS.

HSPG, heparin sulfate proteoglycan; LDR1, low density lipoprotein receptor-related protein 1; AQP4, aquaporin-4

Disease	PiD	PSP	CBD	AGD	GGT	ARTAG	AD	PART	CTE
Common clinical symptoms	Aphasia, several behavioural changes including and personality changes, cognitive changes at later stages of disease.	Balance and motor deficits, dysphagia and aphagia.	Motor problems (often one-sided), aphagia, dysphagia.	Amnesic mild cognitive impairment often accompanied by neuropsychiatric symptoms.	Behavioural changes, mood swings, short-term memory loss.	Often no cognitive impairment or dementia related symptoms. Focal pathology may correlate with specific deficits, especially in the presence of co-pathology.	Dementia; progressive episodic memory deficits; navigational and multi-tasking difficulties; diverse behavioural and personality changes.	Associated with cognitive impairment and mild AD-like symptoms.	Behavioural changes, mood swings, short-term memory loss.
MAPT cause/risk	Mostly sporadic; MAPT mutations (exon 9, 10, 11, 12, 13 and intron 9, 10).	Mostly sporadic, H1/H1c MAPT haplotype increases risk; MAPT mutations (exon 1, 10, and intron 10);	Mostly sporadic; H1 MAPT haplotype increases risk; MAPT mutations (exon 10, 13 & intron 10);	H1 MAPT haplotype may increase risk; MAPT mutations (exon 10)	H1 MAPT haplotype; MAPT mutations (exons 1, 10, 11, intron 10).	<i>Depending on sub-type and classification</i>	Mostly sporadic; APP, PSEN1, PSEN2; No MAPT mutations	<i>Depending on sub-type and classification</i>	<i>Unknown</i> (external causes)
Primary tau isoforms that	3R	4R	4R	4R	4R	4R	3R & 4R	3R & 4R	3R & 4R

accumulate in lesions									
Affected brain regions	Frontal and temporal cortices.	Precentral cortex, subcortex (globus pallidus, substantia nigra, pontine nuclei, subthalamic nuclei).	Frontal and temporal cortices.	Medial temporal lobe.	Frontal, precentral and/or temporal cortices.	Grey and/or white matter, perivascular, subpial, subependymal.	Entorhinal cortex and hippocampus, spreading to most regions except the cerebellum.	Entorhinal cortex, hippocampus.	Begins focally at depths of cerebral sulci, spreads widely to frontal temporal lobes.
Hallmark astrocytic tau pathology	Ramified	Tufted	Astrocytic plaques	Thorn-shaped & granular fuzzy/bush-like	Globular inclusions	Thorn-shaped & granular fuzzy	<i>None</i>	<i>None</i>	Astrocytic tangles and some thorn-shaped astrocytes.
Cellular localisation of astrocytic tau inclusions	Asymmetric 3R (predominant) or 4R tau inclusions in cell bodies & proximal processes.	Symmetric 4R tau inclusions in proximal processes.	4R tau in distal processes and end feet; thread-like processes are also common.	4R tau inclusions and diffuse staining in cell bodies & proximal-distal processes.	4R globular tau in cell bodies & proximal processes.	4R tau inclusions and diffuse staining in cell bodies & proximal processes.	<i>n/a</i>	<i>n/a</i>	Irregular p-tau lesions (around small vessels).

Astrocytes in Tauopathies

References	Forrest et al., (2018; 2019); Dickson, (2001; 2011); ; Josephs et al., (2011); Ferrer et al., (2014).	Forrest et al., (2018; 2019); Cairns et al., (2007); Kovacs and Budka, (2010).	Forrest et al., (2018; 2019); Dickson et al., (2011); Ling et al., (2016).	Forrest et al., (2018; 2019); Botez et al., (1999); Saito et al., (2004).	Forrest et al., (2018; 2019); Ahmed et al., (2013).	Forrest et al., (2018; 2019); Kovacs et al., (2016, 2017, 2018, 2020).	Guerreiro et al., (2012); Braak and Braak, (1991); Braak et al., (2011).	Forrest et al., (2018; 2019); Crary et al., (2014); Jellinger et al., (2015).	Forrest et al., (2018; 2019); Stein et al., (2014); McKee et al., (2015; 2016).
------------	---	--	--	---	---	--	--	---	---

Table 1: Overview of the main clinical, genetic, molecular, and pathological features of tauopathies, including description of astrocyte abnormalities.

PiD, Pick’s disease; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; AGD, argyrophilic grain disease; GGT, globular glial tauopathy; ARTAG, age-related tau astrogliopathy; AD, Alzheimer’s disease; PART, primary age-related tauopathy; CTE, chronic traumatic encephalopathy; 3R, 3-repeat tau; 4R, 4-repeat tau.